Science |AI Proteins
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
October 21, 2026 · 8:00 AM · BOSTON
AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC, an affiliate of Astellas Pharma Inc. (TSE: 4503), to discover and develop novel miniprotein-based therapeutics. Under the terms of the agreement, AI Proteins is eligible to receive over $400 million in upfront and milest...
- PublishedOctober 21, 2026 · 8:00 AM
- LocationBOSTON
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →